Buy Mazdutide 6mg
GLP-1/glucagon dual agonist for superior weight loss and metabolic control
Trusted Mazdutide 6mg — Mazdutide is a once-weekly GLP-1/glucagon receptor dual agonist in Phase III trials that produces superior weight loss versus GLP-1 monotherapy by adding thermogenic glucagon activation.
- Dual GLP-1/glucagon receptor activation for superior weight loss
- Increases metabolic rate via glucagon thermogenic signaling
- Reduces liver fat through hepatic fatty acid oxidation
- Appetite suppression from GLP-1 receptor pathway
- 10–15% body weight loss in Phase II trials
COA verified · US domestic shipping
Mazdutide: The GLP-1/Glucagon Dual Agonist Delivering Superior Weight Loss in Phase III Trials
Dual Receptor Mechanism
Combines GLP-1 appetite suppression with glucagon's thermogenic and hepatic fat oxidation effects — addressing both caloric intake and energy expenditure for superior weight loss.
10–15% Body Weight Loss
Phase II data showing 10–15% body weight reduction over 24 weeks — competitive with or exceeding established GLP-1 monotherapy at comparable doses.
Liver Fat Reduction
Glucagon receptor activation specifically reduces hepatic fat accumulation — addressing NAFLD/NASH, the liver disease complication of obesity that GLP-1 agonists address less effectively.
Phase III Pipeline
In active Phase III development — representing the clinically validated next generation of weight loss pharmacology that will reach the market after semaglutide.
The Science Behind Mazdutide 6mg
▸Dual-Receptor Weight Loss Innovation
Mazdutide (IBI362, OXM3) is an oxyntomodulin-based peptide being developed by Innovent Biologics that simultaneously activates both GLP-1 receptors and glucagon receptors. While GLP-1 agonists like semaglutide reduce appetite and slow gastric emptying, the additional glucagon receptor activation increases energy expenditure through hepatic fat oxidation and thermogenesis — addressing both sides of the energy balance equation simultaneously.
▸Mechanism: GLP-1 + Glucagon Synergy
GLP-1 receptor activation reduces appetite, slows gastric emptying, improves insulin secretion, and reduces glucagon. Adding glucagon receptor activation counterintuitively enhances weight loss by increasing metabolic rate, promoting hepatic fatty acid oxidation, and reducing liver fat — effects that GLP-1 alone cannot achieve. Phase II trials demonstrated weight loss of 10–15% body weight over 24 weeks at optimal doses.
▸Phase III Pipeline
Mazdutide is currently in Phase III trials in China and Phase II/III in global markets, positioning it among the next generation of weight loss pharmaceuticals. For researchers and advanced users, it represents a glimpse at dual-mechanism obesity pharmacology that is expected to outperform GLP-1 monotherapy in comparative trials.
Complete Mazdutide 6mg Benefits
- Dual GLP-1/glucagon receptor activation for superior weight loss
- Increases metabolic rate via glucagon thermogenic signaling
- Reduces liver fat through hepatic fatty acid oxidation
- Appetite suppression from GLP-1 receptor pathway
- 10–15% body weight loss in Phase II trials
- Once-weekly dosing for improved adherence
- Addresses both appetite and energy expenditure simultaneously
Mazdutide 6mg Dosing Protocol
Reconstitution: Add 1–2mL bacteriostatic water.
Dosing:
• Research: 0.1–0.3mg subcutaneous weekly (based on Phase II protocols)
• Start: 0.1mg weekly for 4 weeks, increase to 0.2mg, then 0.3mg
• Once-weekly subcutaneous injection
Note: Phase III compound; protocols are based on clinical trial data
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
Mazdutide 6mg
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Stack Mazdutide 6mg With
Weight Loss5-Amino-1MQ 50mg
NNMT inhibitor for fat cell reduction, NAD+ elevation, and metabolic enhancement
Buy 5-Amino-1MQ 50mg — 5-Amino-1MQ is a selective NNMT inhibitor that reduces fat cell size, elevates intracellular NAD+, and enhances metabolic rate — the mechanistically novel small molecule for body composition.
Weight LossAOD9604 5mg
Larger supply HGH lipolytic fragment for extended fat loss protocols
Buy AOD9604 5mg — AOD9604 5mg — extended supply of the hGH lipolytic fragment for longer fat loss cycles without mid-protocol reconstitution.
Weight LossSemaglutide 3mg
GLP-1 receptor agonist for appetite suppression, glucose control, and weight loss
Buy Semaglutide 3mg — Semaglutide 3mg — the GLP-1 receptor agonist behind Ozempic and Wegovy, for appetite suppression, blood glucose control, and significant body weight reduction.